Jennifer A Westwood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer A Westwood has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hollie J Pegram
Department of Immunology, Monash University, Clayton, Australia
1 shared publication - Janelle Sharkey
Department of Immunology, Monash University, Clayton, Australia
1 shared publication - Mark J. Smyth
QIMR Berghofer Medical Research Institute, Brisbane, Australia
1 shared publication - Michael H. Kershaw
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia
1 shared publication - Phillip K. Darcy
Cancer Immunology Program, Peter MacCallum Cancer Centre, Parkville, Australia
1 shared publication - Preethi Mayura Guru
Department of Immunology, Monash University, Clayton, Australia
1 shared publication
Latest Publications
- Open Access
- 28 April 2010
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 8 (1) , 42
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice
Background: Combination immunotherapies can be effective against subcutaneous tumors in mice but the effect against orthotopic malignant disease is less well characterized. In particular, a combination of three agonist antibodies, termed Tri-mAb, consisting of anti-DR5, anti-CD40 and anti-CD137 has previously been demonstrated to eradicate a large proportion of subcutaneous renal cell carcinoma (Renca) tumors (75% long-term survival), but the effect against orthotopic disease is not known.Purpose: To determine the relative response of orthotopic tumors, we inoculated Renca into the kidney followed by treatment with Tri-mAb.Results: We found that orthotopic tumors responded much less to treatment (~13% survival), but a significant improvement in survival was achieved through the addition of IL-2 to the treatment regimen (55% survival). All three agonist antibodies and high dose IL-2, 100,000 IU for up to six doses, were required. CD8+T cells were also required for optimal anti-tumor responses. Coadministration of IL-2 led to enhanced T cell activity as demonstrated by an increased frequency of IFN-gamma-producing T cells in tumor-draining lymph nodes, which may have contributed to the observed improvement of therapy against kidney tumors.Implications: Responses of subcutaneous tumors to immunotherapy do not necessarily reflect how orthotopic tumors respond. The use of combination immunotherapy stimulating multiple facets of immunity and including cytokine support for T cells can induce effective anti-tumor responses against orthotopic and metastatic tumors.
- 28 April 2010
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 8 (1) , 42
Open AccessThree agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice
Background: Combination immunotherapies can be effective against subcutaneous tumors in mice but the effect against orthotopic malignant disease is less well characterized. In particular, a combination of three agonist antibodies, termed Tri-mAb, consisting of anti-DR5, anti-CD40 and anti-CD137 has previously been demonstrated to eradicate a large proportion of subcutaneous renal cell carcinoma (Renca) tumors (75% long-term survival), but the effect against orthotopic disease is not known.Purpose: To determine the relative response of orthotopic tumors, we inoculated Renca into the kidney followed by treatment with Tri-mAb.Results: We found that orthotopic tumors responded much less to treatment (~13% survival), but a significant improvement in survival was achieved through the addition of IL-2 to the treatment regimen (55% survival). All three agonist antibodies and high dose IL-2, 100,000 IU for up to six doses, were required. CD8+T cells were also required for optimal anti-tumor responses. Coadministration of IL-2 led to enhanced T cell activity as demonstrated by an increased frequency of IFN-gamma-producing T cells in tumor-draining lymph nodes, which may have contributed to the observed improvement of therapy against kidney tumors.Implications: Responses of subcutaneous tumors to immunotherapy do not necessarily reflect how orthotopic tumors respond. The use of combination immunotherapy stimulating multiple facets of immunity and including cytokine support for T cells can induce effective anti-tumor responses against orthotopic and metastatic tumors.